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The tyrosine phosphatase SHP-1 negatively influences endothelial function, such as VEGF
signaling and reactive oxygen species (ROS) formation, and has been shown to influence
angiogenesis during tissue ischemia. In ischemic tissues, hypoxia induced angiogenesis is
crucial for restoring oxygen supply. However, the exact mechanism how SHP-1 affects en-
dothelial function during ischemia or hypoxia remains unclear. We performed in vitro endo-
thelial cell culture experiments to characterize the role of SHP-1 during hypoxia.
Results
SHP-1 knock-down by specific antisense oligodesoxynucleotides (AS-Odn) increased cell
growth as well as VEGF synthesis and secretion during 24 hours of hypoxia compared to
control AS-Odn. This was prevented by HIF-1α inhibition (echinomycin and apigenin). SHP-
1 knock-down as well as overexpression of a catalytically inactive SHP-1 (SHP-1 CS) fur-
ther enhanced HIF-1α protein levels, whereas overexpression of a constitutively active
SHP-1 (SHP-1 E74A) resulted in decreased HIF-1α levels during hypoxia, compared to
wildtype SHP-1. Proteasome inhibition (MG132) returned HIF-1α levels to control or wild-
type levels respectively in these cells. SHP-1 silencing did not alter HIF-1αmRNA levels. Fi-
nally, under hypoxic conditions SHP-1 knock-down enhanced intracellular endothelial
reactive oxygen species (ROS) formation, as measured by oxidation of H2-DCF and
DHE fluorescence.
Conclusions
SHP-1 decreases half-life of HIF-1α under hypoxic conditions resulting in decreased cell
growth due to diminished VEGF synthesis and secretion. The regulatory effect of SHP-1 on
HIF-1α stability may be mediated by inhibition of endothelial ROS formation stabilizing HIF-
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1α protein. These findings highlight the importance of SHP-1 in hypoxic signaling and its po-
tential as therapeutic target in ischemic diseases.
Introduction
Src homology region 2 domain-containing phosphatase-1 (SHP-1), a nonreceptor-type protein
tyrosine phosphatase (PTP), is mainly expressed in hematopoietic cells and epithelial tissue
like endothelial cells [1, 2]. We previously showed the importance of SHP-1 in endothelial
function and homeostasis. We found SHP-1 to protect the endothelium from adhesion mole-
cule upregulation and thrombosis under inflammatory conditions in vitro and in vivo [3]. Fur-
thermore, another study from our group showed that SHP-1 also negatively regulates VEGF
mediated endothelial cell signaling, by inhibiting the formation of reactive oxygen species
(ROS) [2]. ROS is important for angiogenic processes and conditions where angiogenesis is in-
duced, such as hypoxia or ischemia, are known to increase endothelial ROS formation [4].
Hypoxia dependent vessel sprouting (angiogenesis) is mediated by the transcription factor
Hypoxia inducible factor-1 (HIF-1) [4–6], a major regulator of cellular adaption to hypoxia
consisting of an oxygen dependently regulated α-subunit and a constitutively expressed β-sub-
unit [7, 8]. Under normoxic conditions the HIF-1α subunit is marked for degradation by pro-
lylhydroxylases and subsequently degraded by the proteasomal degradation system. Under
hypoxic conditions however, the degradation is inhibited with accumulation of HIF-1α as a re-
sult [9, 10]. ROS have been shown to stabilize HIF-1α during hypoxia by preventing its degra-
dation [11]. During hypoxia HIF-1 functions as a transcription factor for proteins such as the
vascular endothelial growth factor (VEGF), which is of crucial importance for hypoxia driven
endothelial cell proliferation. It has been shown that HIF-1 mediated VEGF secretion is essen-
tial for hypoxia induced endothelial cell proliferation by an autocrine loop mechanism [6, 12].
Interestingly, SHP-1 has been shown to inhibit endothelial cell proliferation and survival under
hypoxic conditions [13, 14] and knock-down of SHP-1 results in improved angiogenesis in
hindlimb ischemia [14]. Moreover, in vivo studies show the potential of SHP-1 inhibition to
decrease necrosis size in myocardial infarction [15, 16] and ischemic stroke [17].
These findings highlight the importance of SHP-1 in hypoxia and ischemic diseases as well
as its therapeutic potential. However, the mechanism how SHP-1 mediates these effects in hyp-
oxia/ ischemia is not fully understood. In particular an involvement of SHP-1 in the regulation
of HIF-1α has not yet been investigated.
In this study, we show that an inhibition of SHP-1 in human microvascular endothelial cells
(HMEC) increases endothelial proliferation and VEGF secretion during hypoxia. Furthermore,




Mouse HIF-1α antibody used for immunoprecipitations was purchased from BD Biosciences
(#610959, Heidelberg, Germany) and rabbit HIF-1α antibody used for western blotting was ob-
tained from Merck Millipore (#04-1006,Darmstadt, Germany). Mouse (D-11, #sc-7289) and
Rabbit (C-19, #sc-287) SHP-1 for immunoprecipitations and western blotting respectively and
mouse VEGF (C-1, #sc-7269) antibodies were from Santa Cruz biotechnology (Heidelberg,
Germany). Mouse phospho-tyrosine antibody was fromMerck Millipore (# 05-321,
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Darmstadt, Germany). Beta-Actin antibody was from Cell Singaling Technology (#4970, Dan-
vers, MA, USA). Horseradish peroxidase-conjugated antibodies were from Calbiochem
(Darmstadt, Germany) and fluorescently labeled secondary antibodies were from Invitrogen
(Darmstadt, Germany). MG132 and Echinomycin were fromMerck (Darmstadt, Germany).
All other chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany).
Cell lines and cell culture
HMEC were provided by Ades et al.[18] and cultured as described previously [19]. HMEC
were put on starvation medium (DMEM, 1% fetal calf serum) 24 hours prior to experiments
unless stated otherwise.
Hypoxic environment
Cells were exposed to hypoxia in an appropriate chamber purchased from Cell Systems
(Troisdorf, DE), which was flooded with 15–20 l/min of an anoxic gas mixture (5% CO2, 95%
N2) for 4 minutes. The cell medium was bubbled with the same gas mixture for 30 minutes be-
fore usage. The hypoxia chamber was placed in an incubator at 37° C for either 4 or 24 hours.
O2 partial pressure in the cell medium reached an equilibrium after appr. 30–60 minutes at
8 plusmn;2 mmHg, which equals an O2 concentration of 1±0.2%. This hypoxic environment
was shown to induce HIF-1α expression after 4 hours, as well as VEGF synthesis and secretion
after 24 hours.
Transfection of antisense oligonucleotides (AS Odn)
HMEC were transfected with specific SHP-1 AS Odn (5‘-ccttgagcagggtctctgcatcc-3‘) or control
Odn (5‘-cccttatttactactttcgc-3‘) respectively in a concentration of 70 nM using the magnetofec-
tion method [20, 21] and the Effectene kit from Qiagen (Hilden, Germany) as previously de-
scribed [2]. Odn were synthesized by Eurofins MWGOperon (Ebersberg, Germany).
Experiments were performed 24 hours after transfection.
Plasmid transfer
HMEC were transfected with either SHP-1 wildtype, SHP-1 CS (dominant negative form due
to mutation of Cys453 to Ser453 in the catalytic domain) or SHP-1 E74A (constitutively active
form due to mutation of the Glu74 to Ala74 in the N-SH2 domain) plasmids using PeqFECT
DNA (PEQLAB Biotechnologie Erlangen, Germany) according to the manufacturer’s protocol.
Experiments were performed 48 to 72 hours after transfection. Plasmids were obtained from
Addgene (www.addgene.org).
Cell extracts for western blot analysis and immunoblotting
Protein lysates were prepared and protein content quantified as described previously [2]. Ly-
sates were then subjected to western blot analysis as described elsewhere [2].
Immunofluorescence staining
For immunofluorescent microscopy of SHP-1 and HIF-1α, cells were grown to confluence on
8-well microscope slides from IBIDI (Martinsried, Germany) and stained and visualized as pre-
viously described [22]. Quantification of fluorescent intensity was performed by pixel measure-
ments using AxioVision 4.8 from Zeiss (Jena, Germany).
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Immunoprecipitation
Immunoprecipitations were performed using μMACS Protein GMicroBeads and MACS sepa-
ration columns fromMiltenyi Biotec (Bergisch Gladbach, Germany) according to the manu-
facturer’s protocol. The precipitates were quantified by western blotting.
Proliferation measurement
To quantify proliferation and cell viability protein concentrations of single wells of a 24-well
plate were measured by Biuret method as previously described [2].
Quantification of VEGF synthesis and secretion
VEGF synthesis was determined by flow cytometry. Cells were exposed to hypoxia/normoxia
without prior starvation. Subsequently, cells were detached using Accutase (PAA Laboratories,
Pasching, Austria), pelleted, fixated with 5% formaldehyde solution for 10 min, pelleted, per-
meabilized with 0.1% Triton solution for 5min, rinsed, incubated with VEGF antibody for 1
hour (1:200 in Phosphate buffered saline (Pbs) supplemented with calcium), rinsed and incu-
bated with FITC labeled secondary antibody (1:400 in Pbs supplemented with calcium) for 30
min, pelleted and dissolved in Pbs supplemented with calcium for measurement by flow cy-
tometry using a FACS Canto II (BD Biosciences, Heidelberg, Germany). To control for back-
ground staining, control cells were stained with secondary antibody only.
VEGF secretion in the supernatant was measured using Quantikine Human VEGF Immu-
noassay from R&D Systems (Minneapolis, MN, USA) according to the manufacturer’s
protocol.
RNA isolation and quantitative real time PCR
Total RNA was isolated using the PeqGOLD total RNA kit (Peqlab Erlangen, Germany). A
total of 2 μg RNA was transcribed to DNA by using SuperScript Reverse Transcriptase (Life
Technologies, DE). Real time PCR was performed on TaqMan ABI 7700 (PE Applied Biosys-
tems, Darmstadt, DE). TaqMan gene expression assays for HIF-1α (#Hs00153153_m1) and
GAPDH (#4310884E) were used (Life Technologies, DE).
Measurement of reactive oxygen species (ROS)
Intracellular ROS formation was analyzed by quantifying the ROS dependent oxidation of H2–
2’, 7’-Dichlorofluorescein (H2-DCF) to fluorescent DCF. Cells were incubated with 20 μM
H2DCF diacetate during normoxia/hypoxia, detached using Accutase (PAA Laboratories,
Pasching, Austria), pelleted, rinsed and dissolved in PBS supplemented with calcium for instant
measurement by flow cytometry using a FACS Canto II (BD Biosciences, Heidelberg, Ger-
many). Superoxide production was detected by dihydroethidium (DHE) fluorescence. Cells
were incubated with DHE (20 μM) during hypoxia/normoxia followed by detachment using
Accutase (PAA Laboratories, Pasching, Austria). Cells were pelleted, rinsed and dissolved in
PBS supplemented with calcium for instant measurement by flow cytometry using a FACS
Canto II (BD Biosciences, Heidelberg, Germany). Median fluorescent units were used for
the analysis.
Statistical analysis
Data were analyzed using Student's t-test, Wilcoxon rank sum test or one-way ANOVA as ap-
propriate. All data are presented as means ± SEM. Results were considered significant at an
error probability level of P< 0.05.
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Results
Expression and localization of SHP-1 and HIF-1α in HMEC
First, we analyzed expression and localization of SHP-1 and HIF-1α in HMEC during nor-
moxia and hypoxia. HIF-1α protein was induced by 1h and 4h hypoxia (western blot: n = 4,
Fig. 1A). HIF-1α induction by 4h hypoxia could be confirmed by immunofluorescent staining
(p<0.001; immunofluorescence: n = 6, Fig. 1B). On the contrary, SHP-1 protein was expressed
during normoxic as well as hypoxic conditions but showed a slight increase in expression upon
hypoxia (immunofluorescence: p<0.05; n = 6, Fig. 1B). Furthermore, analysis revealed that
both proteins are predominantly located in the nucleus of HMEC with only moderate expres-
sion in the cytoplasm (n = 6, Fig. 1B). Additionally, immunoprecipitation of SHP-1 was per-
formed and HIF-1α was detected in the precipitate (n = 6, Fig. 1C). SHP-1 protein could only
be detected after performing immune precipitation with an antibody recognizing SHP-1 and
not in 30μg of whole cell lysates indicating a relatively low expression level in endothelial cells.
To investigate if HIF-1α is tyrosine phosphorylated in endothelial cells, immunoprecipitations
of HIF-1α was performed followed by detection of phospho-tyrosine residues by western blot.
As seen in Fig. 1D (upper blot lane 4), no HIF-1α was precipitated when using an IgG isotype
control antibody and HIF-1α could successfully be precipitated when using a specific antibody
(upper blot lane 6, n = 3). To analyze possible differences in HIF-1α tyrosine phosphorylation
in normoxia and hypoxia, the immunoprecipitation was performed again in cells treated with
the proteasome inhibitor MG132 to achieve equal HIF-1α amounts during both conditions. As
seen in Fig. 1D (lower blot) HIF-1α is tyrosine phosphorylated but no difference between nor-
moxia and hypoxia could be detected (n = 3).
SHP-1 regulates endothelial cell growth and VEGF synthesis during
hypoxia
To investigate the role of SHP-1 on endothelial cell growth under hypoxic conditions SHP-1
was knocked-down by transfecting HMEC with specific antisense oligodesoxynucleotides
(AS-Odn). The efficacy of this technique in endothelial cells has been described earlier by our
group [2].
Silencing of SHP-1 led to increased cell growth during 24 hours of hypoxia (p<0.05; n = 18,
Fig. 2A) compared to treatment with control AS-Odn (n = 18). As VEGF is known to be an im-
portant factor for endothelial proliferation [23] and its synthesis is enhanced by hypoxia [23–
25], we also measured the intracellular VEGF concentration as well as VEGF secretion in the
supernatant in dependence of SHP-1 expression. Knock-down of SHP-1 resulted in a signifi-
cant increase in the amount of intracellular (p<0.05; n = 10, Fig. 2B) and secreted (p<0.01;
n = 8, Fig. 2C) VEGF during 24h hypoxia compared to control AS-Odn treatment. Since HIF-
1α is known to be an important mediator of hypoxia driven cellular responses and an impor-
tant transcription factor for VEGF under these conditions [8] we next asked whether SHP-1
may regulate cell growth and VEGF production via the HIF-1 pathway. Treatment with echi-
nomycin, a pharmacological inhibitor of HIF-1, during hypoxia completely abolished the in-
crease in cell growth resulting from SHP-1 knock-down during 24h hypoxia (p<0.05; n = 11,
Fig. 2D) in comparison to cells treated with control AS-Odn. Furthermore, the elevation of in-
tracellular VEGF concentration (p<0.05; n = 10, Fig. 2B) as well as amount of secreted VEGF
(p<0.05; n = 8, Fig. 2C) by SHP-1 knock-down was also prevented by echinomycin. Finally,
this effect was confirmed when using another pharmacological inhibitor of HIF-1α, apigenin
(p<0.05; n = 10, Fig. 2B and C).
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SHP-1 regulates HIF-1α protein levels during hypoxia in HMEC
As cell growth enhancement and increased VEGF synthesis by SHP-1 knock-down could be
prevented by echinomycin, we next analyzed the effect of SHP-1 on HIF-1α protein levels. In
cells treated with control AS-Odn hypoxia increased HIF-1α protein levels (n = 4, Fig. 3A), as
expected. Interestingly, the induction of HIF-1α by hypoxia was even further enhanced by
SHP-1 knock-down (p<0.05; n = 4, Fig. 3A). To confirm these data, HMECs were transfected
with pDNA expressing either wildtype (WT), catalytically inactive (CS) or constitutively active
(E74A) SHP-1. Compared to cells expressing the SHP-1 WT construct, overexpression of the
inactive SHP-1 mutant (CS) resulted in increased HIF-1α protein levels (p<0.05; n = 8,
Fig. 3B), whereas transfection with the constitutively active (E74A) SHP-1 construct led to de-
creased HIF-1α levels (p<0.05; n = 9, Fig. 3B). Having observed an influence of SHP-1 activity
on HIF-1α protein levels, we next investigated whether SHP-1 influences the synthesis or the
degradation of HIF-1α. Consequently, we assessed the transcription of HIF-1α by qRT-PCR.
As shown in Fig. 3C hypoxia itself decreased the amount of HIF-1αmRNA compared to nor-
moxic controls (p<0.05; n = 10), whereas SHP-1 knock-down had no additional effect in any
of the two conditions (n = 10). Next, we analyzed translation and degradation of HIF-1α. As
expected, treatment of HMEC with MG132 to block proteasomal degradation of HIF-1α fur-
ther increased the amount of HIF-1α in hypoxic HMEC under control conditions (p<0.05;
n = 4, Fig. 3D). However, the additional increase in HIF-1α protein level previously observed
after SHP-1 knock-down could no longer be detected upon treatment with MG132 (n = 4,
Fig. 3D). Equivalent to this, after MG132 treatment of cells expressing SHP-1 CS HIF-1α levels
were returned to WT levels (n = 8, Fig. 3E). In accordance to this, the lost HIF-1α accumula-
tion in cells expressing E74A was rescued back to WT levels when inhibiting proteasomal deg-
radation during hypoxia (n = 8, Fig. 3E).
SHP-1 regulates reactive oxygen species (ROS) formation in HMEC
during hypoxia
As ROS have been shown to be essential for HIF-1α stability by inhibiting the activity of prolyl
hydroxylases [11, 26, 27] and as we showed in a previous study that SHP-1 negatively regulates
ROS production in non-stimulated and VEGF-treated EC [2], we hypothesized that SHP-1
may regulate the accumulation of HIF-1α protein by reducing ROS levels. Hence, we tested
whether SHP-1 also effects endothelial ROS formation during hypoxia detecting the oxidation
of H2DCF. SHP-1 silencing resulted in an increase in ROS formation (+ 15%) during hypoxia
(p<0.001; n = 12, Fig. 4A) compared to control treatment. As we previously showed that SHP-
1 regulates VEGF dependent superoxide production, we next investigated if SHP-1 has an im-
pact on superoxide production during hypoxia by detecting dihydroethidium (DHE) fluores-
cence. As shown in Fig. 4B, SHP-1 knock-down also increased superoxide levels during
hypoxia compared to treatment with control AS (p<0.05, n = 8).
Fig 1. SHP-1 expression and localization during hypoxia. (A) The induction of HIF-1α protein levels by 1h
and 4h hypoxia was confirmed by western blot (n = 4). (B) HIF-1α (green) and SHP-1 (red) were detected by
immunofluorescence staining. DAPI (blue) was used to visualize nuclei. HIF-1α was induced by hypoxia
(***p<0.001; n = 6). SHP-1 expression was also slightly induced by hypoxia (p<0.05; n = 6). Both SHP-1
and HIF-1α were shown to be predominantly located in the nucleus with moderate expression in the
cytoplasm. Graphs next to photos show fluorescent intensities of SHP-1 and HIF-1α (n = 6 of 6 visual fields/
sample) (C) Immunoprecipitation was performed for SHP-1. HIF-1α could be detected in precipitates of SHP-
1 (n = 6). IgG: IgG isotype control antibody. (D) HIF-1α could successfully be immunoprecipitated by a
specific antibody (lane 6 upper blot) and is tyrosine phosphorylated under normoxia and hypoxia as seen in
MG132 (10μM) treated cells (lane 3 and 4 lower blot, n = 3). IgG: IgG isotype control antibody.
doi:10.1371/journal.pone.0121113.g001
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Discussion
The nonreceptor-type protein tyrosine phosphatase SHP-1 has been recognized as potential
target to treat ischemic diseases [14–17, 28, 29]. Regulatory processes in which SHP-1 is in-
volved during hypoxia are not fully understood. This study adds new aspects to the role of
SHP-1 in endothelial hypoxic signaling and further underlines its potential as therapeutic tar-
get in ischemic diseases. This is the first study to show that SHP-1 is not only involved in
VEGF receptor signaling, but that it also plays a crucial role in VEGF synthesis and secretion
during hypoxia by regulating the transcription factor HIF-1.
In vivo studies of other groups showed an increased expression of SHP-1 upon ischemia in
myocardial [15] and muscle cells [14], as well as in astrocytes [30]. An ex-vivo study working
with retinal explants did not see any changes in SHP-1 expression or activity upon hypoxia
[31]. In this study, we could only detect a moderate influence of 4h hypoxia on SHP-1 expres-
sion in HMEC. The stronger induction of SHP-1 upon hypoxia observed by others might be
cell type specific or might only occur after longer exposure to hypoxia and not in acute hypoxia
(4h) as used here. However, acute hypoxia is of great interest as it reflects conditions occurring
in acute arterial occlusion like myocardial infarction. Consistent with the fact that SHP-1 and
HIF-1α contain a nuclear localization signal (NLS) [32, 33] our data show that both proteins
are mainly located in the nucleus of the endothelial cells with moderate expression in the cyto-
plasm. SHP-1 protein could only be detected after concentration by immunoprecipitation.
This is probably due to lower SHP-1 expression levels in endothelial cells. Indeed, SHP-1 has
been described to mainly be expressed in hematopoietic cells and thus show lower expression
in endothelial cells. Tyrosine phosphorylation of HIF-1α could be detected but did not change
between normoxic and hypoxic conditions. As HIF-1α is degraded during normoxia, the tyro-
sine phosphorylation may not be important under these conditions. Under hypoxic conditions
however, tyrosine phosphorylated HIF-1αmay play a role, as HIF-1α accumulates and may so
constitute a binding site for SH2-containing proteins, such as SHP-1. Interestingly, we could
also detect HIF-1α in precipitates of SHP-1. Thus, both proteins may even be part of the same
protein complex
Upon SHP-1 silencing we observed increased endothelial cell growth under hypoxic condi-
tions, which is in line with earlier studies [13, 14]. These earlier studies identified increased
VEGFR-2 signaling [14] and increased expression of pro-angiogenic and anti-apoptotic factors
[13] by SHP-1 knock-down, as being responsible for the observed effects highlighting the im-
portance of SHP-1 as negative regulator of different pathways e.g. VEGF signaling. Here, we
identified another aspect of how SHP-1 regulates endothelial cell growth during hypoxic condi-
tions that has not been observed before. We found that SHP-1 inhibits synthesis of endothelial
VEGF by accelerating HIF-1α protein degradation under hypoxic conditions. Our data show
that SHP-1 knock-down increases intracellular and secreted VEGF. This is particularly inter-
esting as endothelial VEGF is known to be crucial for hypoxia induced EC growth in terms of
Fig 2. SHP-1 knock-down increased cell growth and VEGF synthesis and secretion during hypoxia.
(A) Cell growth was quantified by measurement of total protein content of single wells. Knock-down of SHP-1
resulted in increased cell growth during 24 hours of hypoxia compared to control Odn (*p<0.05, n = 18). (B)
Intracellular VEGF was measured by FACS. SHP-1 knock-down led to increased levels of intracellular VEGF
after 24 hours of hypoxia (*p<0.05, n = 10), which was blocked by echinomycin (Ecm, 10ng/ml) (*p<0.05 vs.
control Odn; n = 10) as well as apigenin (Apg, 50μM) (*p<0.05 vs. control Odn; n = 10). (C) SHP-1 knock-
down resulted in elevated VEGF concentration in supernatants of hypoxic HMECs, as measured by ELISA
(*p<0.01, n = 18). Inhibition of HIF-1α activity by echinomycin (10ng/ml) or apigenin (50μM) reduced this in
both control Odn and SHP-1 AS-Odn treated cells (*p<0.05 vs. control Odn; n = 8). (D) The increased cell
growth during hypoxia by SHP-1 knock-down could be prevented by adding the HIF-1 inhibitor echinomycin
(Ecm, 10 ng/ml) (*p<0.05, n = 11).
doi:10.1371/journal.pone.0121113.g002
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Fig 3. SHP-1 destabilizes HIF-1α protein during hypoxia. (A) HIF-1α protein levels were further enhanced
by SHP-1 knock-down during hypoxia (4h) (*p<0.05, n = 4, lane 4) compared to control conditions (lane 3).
Graph shows the protein band density of HIF-1α in relation to loading control β-Actin. (B) HIF-1α levels in non
transfected cells was compared to SHP-1WT expressing cells showing no influence of transfection on this
(upper blot; n = 4). HMECs expressing inactive SHP-1 (CS) showed increased (*p<0.05; n = 8, lane 2 in
lower blot), whereas expression of constitutively active SHP-1 (E74A) showed decreased (*p<0.05; n = 9,
lane 3 in lower blot) levels of HIF-1α compared to wildtype (WT) SHP-1 (lane 1 in lower blot). Graph shows
HIF-1α protein band density in relation to the loading control β-Actin. (C) HIF-1αmRNAwas quantified by
qRT-PCR. Hypoxia (4h) significantly decreased HIF-1αmRNA compared to normoxic conditions (*p<0.05;
n = 10). However, SHP-1 knock-down had no effect on HIF-1αmRNA levels (n = 10). (D) The regulatory
effect of SHP-1 on HIF-1α levels shown in (A) could not be observed when protein degradation was
prevented by using the proteasome inhibitor MG132 (10μM) (n = 4). Graph shows HIF-1α protein band
density in relation to the loading control β-Actin. (E) Differences in HIF-1α translation between cells
expressing catalytic inactive (CS) and wildtype (WT) SHP-1 were not detected (n = 8) and the decreased HIF-
1α accumulation seen in cells expressing constitutively active (E74A) SHP-1 was rescued upon inhibition of
proteasomal inhibition (MG132 10μM) (n = 8).
doi:10.1371/journal.pone.0121113.g003
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Fig 4. SHP-1 knock-down enhances ROS production during hypoxia. (A) SHP-1 knock-down enhanced
ROS formation during hypoxia (*p<0.001; n = 12) compared to control AS-Odn treated cells. (B) SHP-1
knock-down enhanced hypoxia induced intracellular superoxide production (*p<0.05, n = 8), as assessed by
DHE fluorescence.
doi:10.1371/journal.pone.0121113.g004
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an autocrine loop mechanism [6, 12]. Furthermore, hypoxia has been shown to enhance the ex-
pression of the VEGF receptors [34, 35], which also contributes to the increased proliferative
response during this condition. Cell growth and VEGF synthesis during hypoxia were impaired
by echinomycin and apigenin, both pharmacological inhibitors of HIF-1α activity [36], indicat-
ing that both increased cell growth and VEGF synthesis are, at least partially, HIF-1αmediated.
Interestingly, inhibition of HIF-1α by echinomycin completely blocked VEGF synthesis and
secretion, whereas apigenin was shown to have a greater effect on VEGF synthesis and to a less-
er extent, although still significant, on VEGF secretion. The same phenomenon can be seen in
other studies using apigenin [37, 38], an effect which may be concentration dependent, as seen
in the study of Mirzoeva et al. [38]. Nevertheless, the increase in hypoxic cell growth, VEGF
synthesis and secretion by SHP-1 knock-down could be prevented by HIF-1α inhibition using
echinomycin and apigenin, suggesting that SHP-1 is part of these HIF-1α dependent processes.
Analyzing the role of SHP-1 on HIF-1α protein levels we found that SHP-1 knock-down in-
deed further enhanced the induction of HIF-1α by hypoxia. The same results were obtained
transfecting HMEC with an inactive SHP-1 construct. These findings were in accordance with
the fact that expression of a construct containing a constitutively active SHP-1 decreased HIF-
1α levels compared to expression of the wildtype construct. This experiment further confirms
that the catalytic activity of SHP-1 is responsible for the observed effect and not merely expres-
sion of the protein. To the best of our knowledge this is the first time an explicit role of SHP-1
on HIF-1α induction in hypoxia and in endothelial cells is described. When investigating
whether SHP-1 influences synthesis or degradation of HIF-1α we found that neither in nor-
moxia nor in hypoxia SHP-1 knock-down seemed to influence HIF-1α transcription. However,
upon inhibition of the HIF-1α degradation pathway, to investigate effects on translation as
well as degradation, a difference in HIF-1α levels between SHP-1 knock-down cells and control
cells or SHP-1 WT and SHP-1 CS expressing cells respectively could no longer be detected.
This demonstrates that SHP-1 does not influence the translation of HIF-1α protein. Further-
more, as the decrease in HIF-1α levels in cells expressing constitutively active SHP-1 could be
rescued by MG132 treatment, SHP-1 rather influences the degradation of HIF-1α. Regarding
the mechanism how SHP-1 influences HIF-1α protein levels we know from previous studies
that reactive oxygen species (ROS) stabilize HIF-1α under hypoxic [11, 26, 27] and normoxic
[39–42] conditions. Previous data from our group showed that SHP-1 is a negative regulator of
endothelial ROS formation under normoxic conditions [2]. In this study we could show that
SHP-1 silencing also increases intracellular ROS formation, particularly superoxide molecules,
during hypoxia. Hence, it is possible and plausible that the negative regulatory effect of SHP-1
on HIF-1α is the result of SHP-1 inhibiting endothelial ROS formation. The exact mechanism
behind this regulation still needs to be elucidated and is part of our further research.
We conclude that SHP-1 promotes HIF-1α degradation under hypoxic conditions leading
to a reduction in VEGF synthesis and secretion and thus impaired EC proliferation. A negative
regulation of ROS by SHP-1 may have a potential mediator role in this signaling cascade. SHP-
1 seems to prevent cellular overstimulation under hypoxic conditions and, hence, may be of
importance in proliferative diseases e.g. in tumor angiogenesis. Finally, as inhibition of SHP-1
activity under hypoxia seems to be proangiogenic, SHP-1 may indeed constitute an interesting
therapeutic target for ischemic diseases.
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